Tag: FAP

Eplontersen may stabilize, slow heart damage in FAP patients

A little more than a year of treatment with eplontersen was found to stabilize or even improve the heart’s structure and function in people with familial amyloid polyneuropathy (FAP) who also were experiencing symptoms of heart disease, known as cardiomyopathy. That’s according to an exploratory analysis of data from the…

Continue Reading Eplontersen may stabilize, slow heart damage in FAP patients

Criteria for better assessment of rare genetic variants that can lead to hereditary colorectal cancer

APC gene, APC protein, and criteria boundaries and genotype-phenotype correlations. Representation of the APC gene (bottom) and its main protein product (middle) on the reference sequence NM_000038.6 (non-coding exon 1 not shown). The figure shows on the top the boundaries for the application of PVS1, BS3 and BP1 and genotype-phenotype…

Continue Reading Criteria for better assessment of rare genetic variants that can lead to hereditary colorectal cancer

Development of mRNA-Directed Delivery – LNP Delivery System

During the COVID-19 pandemic, the success of mRNA vaccines has greatly propelled the development of mRNA therapeutics. mRNA is a negatively charged nucleic acid that serves as a template for protein synthesis in ribosomes. Despite its utility, the instability of mRNA necessitates appropriate carriers for in vivo delivery. Currently, lipid nanoparticles (LNPs) are…

Continue Reading Development of mRNA-Directed Delivery – LNP Delivery System

Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer | Military Medical Research

Zhu J, Ke Y, Liu Q, Yang J, Liu F, Xu R, et al. Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy. Nat Commun. 2022;13(1):7466. Article  CAS  PubMed  PubMed Central  Google Scholar  Evans ER, Bugga P, Asthana V, Drezek R. Metallic nanoparticles for cancer…

Continue Reading Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer | Military Medical Research

Gene editing therapy leads to sustained drop in toxic TTR protein

A single infusion of NTLA-2001, an experimental gene editing therapy, generally is safe and leads to a marked reduction in blood levels of the harmful transthyretin (TTR) protein in people with familial amyloid polyneuropathy (FAP) and ATTR amyloidosis with cardiomyopathy (ATTR-CM). These updated, interim data cover 65 of 72 patients…

Continue Reading Gene editing therapy leads to sustained drop in toxic TTR protein

Phase 3 trial of NTLA-2001 for ATTR-CM to launch by year’s end

Intellia Therapeutics is launching a pivotal Phase 3 clinical trial in the U.S. to evaluate the safety and effectiveness of its investigational gene-editing therapy NTLA-2001 in people with ATTR amyloidosis with cardiomyopathy (ATTR-CM). The study, which is expected to start by the end of the year, follows the recent approval…

Continue Reading Phase 3 trial of NTLA-2001 for ATTR-CM to launch by year’s end

Radiopharmaceuticals market booms with funding surge

Emerging as a new class of drugs, radiopharmaceuticals are all the rage in cancer treatment research, at present. And now, with American biotech Nucleus RadioPharma raising $56 million to streamline its supply chains and make the drugs more accessible, it seems like the radiopharmaceutical market might be onto something big….

Continue Reading Radiopharmaceuticals market booms with funding surge

Eplontersen’s efficacy in FAP supported by full Phase 3 trial results

More than a year of treatment with the experimental therapy eplontersen significantly reduces blood levels of transthyretin — the protein that accumulates to toxic levels in familial amyloid polyneuropathy (FAP) — eases nerve damage-related disability, and improves quality of life for patients. That’s according to the full results of the…

Continue Reading Eplontersen’s efficacy in FAP supported by full Phase 3 trial results

Transient naive reprogramming corrects hiPS cells functionally and epigenetically

Cell culture All cell lines used and derived by different approaches in this study are listed in Supplementary Table 1. Detailed information about the experimental design, materials and reagents is presented in the Reporting Summary. Primary human adult dermal fibroblasts (HDFa) from three different female donors were obtained from Gibco…

Continue Reading Transient naive reprogramming corrects hiPS cells functionally and epigenetically

A multi-database based ceRNA regulatory network for gastric cancer prognosis

Abstract Abstract   Objective: Circular RNA(circRNA) is a kind of endogenous non-coding RNA, which may be related to the occurrence and development of cancer. Based on the GEO database, this paper constructs a circRNA as a competitive endogenous RNAs(ceRNAs) that binds with microRNAs (miRNAs) to affect and regulate the expression…

Continue Reading A multi-database based ceRNA regulatory network for gastric cancer prognosis

Strategies to therapeutically modulate cytokine action

Cohen, S., Bigazzi, P. E. & Yoshida, T. Commentary. Similarities of T cell function in cell-mediated immunity and antibody production. Cell Immunol. 12, 150–159 (1974). Article  CAS  PubMed  Google Scholar  Keegan, A. D. & Leonard, W. J. in Paul’s Fundamental Immunology 8th edn, ch. 9 (eds Flajnik, M. F., Singh,…

Continue Reading Strategies to therapeutically modulate cytokine action

Lymph Node Fibroblasts May Suppress T-Cell Function in DLBCL

The immunosuppressive role of fibroblastic reticular cells (FRCs) in diffuse large B-cell lymphoma (DLBCL) is detailed in new research published in The Journal of Clinical Investigation. According to the study’s authors, these findings could have implications for disease pathogenesis and for optimizing immunotherapy in patients with DLBCL. The disease has…

Continue Reading Lymph Node Fibroblasts May Suppress T-Cell Function in DLBCL

Modelling ligand depletion for simultaneous affinity and binding site quantification on cells and tissue

Cell culture All cells were maintained under standard cell culture conditions (37 °C, 5% CO2, saturated humidity). CHO cells stably transfected with human GIPR (gastric inhibitory polypeptide receptor) were obtained from InSCREENeX GmbH (Germany) and cultured in Dulbecco`s Modified Eagle`s Medium/Nutrient Mixture F-12 Ham (Cat.No. D6421, Sigma) supplemented with 5% fetal bovine…

Continue Reading Modelling ligand depletion for simultaneous affinity and binding site quantification on cells and tissue

BMPER is a marker of adipose progenitors and adipocytes and a positive modulator of adipogenesis

Human subject characteristics Visceral (greater omental) adipose tissue samples were obtained in consented patients for our University of Utah Institutional Review Board (IRB)-approved obesity biorepository at the time of laparoscopic bariatric surgery (obesity group) or laparoscopic abdominal surgery for non-cancerous, non-infected general surgery indications (lean group). Patients were fasted for…

Continue Reading BMPER is a marker of adipose progenitors and adipocytes and a positive modulator of adipogenesis

Onpattro shows benefits for 1.5 years in ATTR cardiomyopathy trial | Therapy seen to slow down disability in people with ATTR-CM

Treatment with Onpattro (patisiran) for 1.5 years leads to sustained reductions in disability progression among people with ATTR amyloidosis with cardiomyopathy (ATTR-CM), or damage to the heart. That’s according to interim data from the ongoing open-label extension (OLE) portion of the Phase 3 APOLLO-B clinical trial (NCT03997383). That trial’s initial…

Continue Reading Onpattro shows benefits for 1.5 years in ATTR cardiomyopathy trial | Therapy seen to slow down disability in people with ATTR-CM

Molecular Partners presenting positive solid tumor data

Molecular Partners AG will present additional positive data from the ongoing phase 1 study of MP0317, a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP), at the 2023 ASCO (American Society of Clinical Oncology) annual meeting, June 2 to…

Continue Reading Molecular Partners presenting positive solid tumor data

JCI – Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma

Recent transcriptomic-based analysis of diffuse large B cell lymphoma (DLBCL) has highlighted the clinical relevance of lymph node (LN) fibroblast and tumor-infiltrating lymphocyte (TIL) signatures within the tumor microenvironment (TME). However, the immunomodulatory role of fibroblasts in lymphoma remains unclear. Here, by studying human and mouse DLBCL-LNs, we identify the…

Continue Reading JCI – Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma

KEGG T01001: 11146

Entry 11146             CDS       T01001                                  Symbol GLMN, FAP, FAP48, FAP68, FKBPAP, GLML, GVM, VMGLOM Name (RefSeq) glomulin, FKBP associated protein   KO K23345   glomulin Organism hsa  Homo sapiens (human) Pathway hsa05131   Shigellosis Network nt06521  NLR signaling   Element N00948   Shigella IpaH7.8 to NLRP3 Inflammasome signaling pathway Disease H00531   Venous malformations Brite KEGG Orthology (KO) [BR:hsa00001] 09160 Human Diseases  09171…

Continue Reading KEGG T01001: 11146

AAN 2023: Amvuttra and Onpattro show similar efficacy as FAP treatments | Comparable, sustained drops in transthyretin levels seen

Amvuttra (vutrisiran) and Onpattro (patisiran) showed similar safety and efficacy for familial amyloid polyneuropathy (FAP) patients, according to new analyses from the Phase 3 HELIOS-A trial that supported Amvuttra’s regulatory approval. Both therapies led to similar reductions in transthyretin, the protein that accumulates in FAP, and they were associated with comparable…

Continue Reading AAN 2023: Amvuttra and Onpattro show similar efficacy as FAP treatments | Comparable, sustained drops in transthyretin levels seen

Promising Target Antigens for Cell Therapy of Solid Tumors | Lab Equipment

Initially designed for hematological malignancies, CAR-T therapy is now being expanded to target solid tumors using specialized CAR-T cells that attack specific antigens. Ongoing clinical trials are being conducted to evaluate the efficacy of CAR-T cells targeting FAP, GPC3, HER2, L1CAM, CEACAM5, MSLN, IL-13RA2, EpCAM, PSMA, and EGFR. Studies have…

Continue Reading Promising Target Antigens for Cell Therapy of Solid Tumors | Lab Equipment

Eplontersen for 1 year found to safely ease symptoms in FAP | All goals met in Phase 3 trial of adults, top-line data show

More than one year of treatment with eplontersen safely reduced symptoms of nerve damage and improved quality of life for adults with familial amyloid polyneuropathy (FAP), according to top-line data from the Phase 3 NEURO-TTRansform trial. The experimental therapy from Ionis Pharmaceuticals and AstraZeneca also significantly lowered blood levels of…

Continue Reading Eplontersen for 1 year found to safely ease symptoms in FAP | All goals met in Phase 3 trial of adults, top-line data show

POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

INDIANAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today affirmed that the SPLASH clinical trial for the PSMA-targeted PNT2002 program is not experiencing any manufacturing or drug supply issues…

Continue Reading POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

Coordinated local RNA overexpression of complement induced by interferon gamma in myositis

Differential expression of complement proteins in the different types of IM To define the transcriptomic profiles of patients with different types of IM, we performed bulk RNAseq on muscle biopsies from 132 IM patients, including those with DM (n = 44), AS (n = 18), IMNM (n = 54), and IBM (n = 16). The DM group included…

Continue Reading Coordinated local RNA overexpression of complement induced by interferon gamma in myositis

Transcriptional reprogramming of skeletal muscle stem cells by the niche environment

Isolation of pure populations of MuSCs and niche cells by fluorescence-activated cell sorting (FACS) Hindlimb muscles were dissected from young (4–6 weeks old) or aged (22–26 months old) C57BL/6J (Jackson Laboratory, 000664) mice and minced until no visible tissue chunks were visible. Muscle was then digested in a 15 ml Falcon…

Continue Reading Transcriptional reprogramming of skeletal muscle stem cells by the niche environment

Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer

Mapping molecular changes across malignant transformation We generated single-cell data for 81 samples collected from eight FAP and seven non-FAP donors (Fig. 1a and Supplementary Tables 1 and 2). For each tissue, we performed matched scATAC-seq and snRNA-seq (10x Genomics). We obtained high-quality single-cell chromatin accessibility profiles for 447,829 cells…

Continue Reading Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer